S&P 500   3,941.48
DOW   31,928.62
QQQ   287.24
S&P 500   3,941.48
DOW   31,928.62
QQQ   287.24
S&P 500   3,941.48
DOW   31,928.62
QQQ   287.24
S&P 500   3,941.48
DOW   31,928.62
QQQ   287.24

Inovio Pharmaceuticals (INO) Stock Forecast, Price & News

-0.15 (-7.81%)
(As of 05/24/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
6.80 million shs
Average Volume
5.24 million shs
Market Capitalization
$405.40 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive INO News and Ratings via Email

Sign-up to receive the latest news and ratings for Inovio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Inovio Pharmaceuticals logo

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.


See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$1.77 million
Book Value
$1.55 per share


Net Income
$-303.66 million
Net Margins
Pretax Margin




Free Float
Market Cap
$405.40 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Social Links


Overall MarketRank

2.04 out of 5 stars

Medical Sector

539th out of 1,420 stocks

Surgical & Medical Instruments Industry

62nd out of 138 stocks

Analyst Opinion: 3.0Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Inovio Pharmaceuticals (NASDAQ:INO) Frequently Asked Questions

Is Inovio Pharmaceuticals a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last year. There are currently 5 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Inovio Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INO, but not buy additional shares or sell existing shares.
View analyst ratings for Inovio Pharmaceuticals
or view top-rated stocks.

When is Inovio Pharmaceuticals' next earnings date?

Inovio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Inovio Pharmaceuticals

How were Inovio Pharmaceuticals' earnings last quarter?

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced its earnings results on Tuesday, May, 10th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.28) by $0.08. The biopharmaceutical company earned $0.20 million during the quarter, compared to analysts' expectations of $0.66 million. Inovio Pharmaceuticals had a negative trailing twelve-month return on equity of 76.48% and a negative net margin of 20,479.29%. The company's quarterly revenue was down 46.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.27) earnings per share.
View Inovio Pharmaceuticals' earnings history

When did Inovio Pharmaceuticals' stock split? How did Inovio Pharmaceuticals' stock split work?

Shares of Inovio Pharmaceuticals reverse split on Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.

What price target have analysts set for INO?

5 brokerages have issued twelve-month price targets for Inovio Pharmaceuticals' shares. Their forecasts range from $3.00 to $35.00. On average, they expect Inovio Pharmaceuticals' share price to reach $11.80 in the next year. This suggests a possible upside of 566.7% from the stock's current price.
View analysts' price targets for Inovio Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Inovio Pharmaceuticals' key executives?
Inovio Pharmaceuticals' management team includes the following people:
  • Dr. J. Joseph Kim Ph.D., CEO, Pres & Director (Age 53, Pay $1.31M)
  • Mr. Peter D. Kies, Chief Financial Officer (Age 59, Pay $686.51k)
  • Dr. Jacqueline E. Shea Ph.D., Chief Operating Officer (Age 56, Pay $698.85k)
  • Dr. Laurent M. Humeau Ph.D., Chief Scientific Officer (Age 55, Pay $672.26k)
  • Ben Matone, Director of Investor Relations
  • Mr. Robert L. Crotty J.D., Gen. Counsel (Age 48)
  • Ms. Asli Gevgilili, Chief HR Officer
  • Mr. E. J. Brandreth MBA, Sr. VP of Quality Assurance
  • Dr. Jeffrey Skolnik, Sr. VP of Clinical Devel.
  • Mr. Robert J. Juba Jr., Sr. VP of Biological Manufacturing & Clinical Supply Management
What is J. Joseph Kim's approval rating as Inovio Pharmaceuticals' CEO?

12 employees have rated Inovio Pharmaceuticals CEO J. Joseph Kim on Glassdoor.com. J. Joseph Kim has an approval rating of 82% among Inovio Pharmaceuticals' employees.

What other stocks do shareholders of Inovio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inovio Pharmaceuticals investors own include Novavax (NVAX), Moderna (MRNA), Gilead Sciences (GILD), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Pfizer (PFE), Micron Technology (MU), Sorrento Therapeutics (SRNE) and Vaxart (VXRT).

What is Inovio Pharmaceuticals' stock symbol?

Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."

Who are Inovio Pharmaceuticals' major shareholders?

Inovio Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include State Street Corp (10.49%), BlackRock Inc. (8.14%), Vanguard Group Inc. (5.07%), JPMorgan Chase & Co. (1.55%), Northern Trust Corp (0.85%) and UBS Group AG (0.74%). Company insiders that own Inovio Pharmaceuticals stock include David B Weiner, David B Weiner, Jacqueline Elizabeth Shea, Jong Joseph Kim, Laurent Humeau, Lota S Zoth, Peter Kies and Simon X Benito.
View institutional ownership trends for Inovio Pharmaceuticals

Which major investors are selling Inovio Pharmaceuticals stock?

INO stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Sculptor Capital LP, Sculptor Capital LP, Citigroup Inc., JPMorgan Chase & Co., BlackRock Inc., IMC Chicago LLC, and Royal Bank of Canada. Company insiders that have sold Inovio Pharmaceuticals company stock in the last year include David B Weiner, Jacqueline Elizabeth Shea, Laurent Humeau, Peter Kies, and Simon X Benito.
View insider buying and selling activity for Inovio Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Inovio Pharmaceuticals stock?

INO stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, UBS Group AG, Renaissance Technologies LLC, Triatomic Management LP, Vanguard Group Inc., Group One Trading L.P., Invesco Ltd., and Capital Fund Management S.A..
View insider buying and selling activity for Inovio Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Inovio Pharmaceuticals?

Shares of INO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Inovio Pharmaceuticals' stock price today?

One share of INO stock can currently be purchased for approximately $1.77.

How much money does Inovio Pharmaceuticals make?

Inovio Pharmaceuticals has a market capitalization of $405.40 million and generates $1.77 million in revenue each year. The biopharmaceutical company earns $-303.66 million in net income (profit) each year or ($1.54) on an earnings per share basis.

How many employees does Inovio Pharmaceuticals have?

Inovio Pharmaceuticals employs 317 workers across the globe.

When was Inovio Pharmaceuticals founded?

Inovio Pharmaceuticals was founded in 1979.

What is Inovio Pharmaceuticals' official website?

The official website for Inovio Pharmaceuticals is www.inovio.com.

How can I contact Inovio Pharmaceuticals?

Inovio Pharmaceuticals' mailing address is 660 W. GERMANTOWN PIKE SUITE 110., PLYMOUTH MEETING PA, 19462. The biopharmaceutical company can be reached via phone at (267) 440-4200, via email at [email protected], or via fax at 267-440-4242.

This page was last updated on 5/25/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.